

Professional Summary
Education & Certifications
- Medical Education: Stanford University School of Medicine (2006) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2012) CA
- Residency: Stanford University Internal Medicine Residency (2011) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2012)
Publications
-
Effect of thymine glycol on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II
Tornaletti, S., Maeda, L. S., Lloyd, D. R., Reines, D., & Hanawalt, P. C. (2001). Effect of thymine glycol on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II. JOURNAL OF BIOLOGICAL CHEMISTRY, 276(48), 45367–45371. -
Effect of 8-oxoguanine on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II
Silvia, T. A., Maeda, L. S., Kolodner, R. D., & Hanawalt, P. C. (2004). Effect of 8-oxoguanine on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II. DNA REPAIR, 3(5), 483–94. -
Transcriptional inhibition by an oxidized abasic site in DNA
Wang, Y. L., Sheppard, T. L., Tornaletti, S., Maeda, L. S., & Hanawalt, P. C. (2006). Transcriptional inhibition by an oxidized abasic site in DNA. CHEMICAL RESEARCH IN TOXICOLOGY, 19(2), 234–241. -
Transcription arrest at an abasic site in the transcribed strand of template DNA
Tornaletti, S., Maeda, L. S., & Hanawalt, P. C. (2006). Transcription arrest at an abasic site in the transcribed strand of template DNA. CHEMICAL RESEARCH IN TOXICOLOGY, 19(9), 1215–20. -
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease
Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., … Horning, S. J. (2007). Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. JOURNAL OF CLINICAL ONCOLOGY, 25(25), 3902–7. -
The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma
Maeda, L. S., & Advani, R. H. (2009). The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. CURRENT OPINION IN ONCOLOGY, 21(5), 397–400. -
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE
Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2011). STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(5), 1374–79. -
Current concepts and controversies in the management of early stage Hodgkin lymphoma
Maeda, L. S., Lee, M., & Advani, R. H. (2011). Current concepts and controversies in the management of early stage Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 52(6), 962–71. -
A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma
Warsch, S., Hosein, P. J., Maeda, L. S., Alizadeh, A. A., & Lossos, I. S. (2012). A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. LEUKEMIA & LYMPHOMA, 53(7), 1299–1305. -
Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review
Nair, V. S., Maeda, L. S., & Ioannidis, J. P. A. (2012). Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 104(7), 528–40. -
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., … Wilson, W. H. (2013). Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 368(15), 1408–16. -
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. SCIENCE TRANSLATIONAL MEDICINE, 8(364). -
Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma
Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., … Alizadeh, A. A. (2016). Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. BLOOD. SAN DIEGO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY. -
Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., … Levy, R. (2015). Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. BLOOD. AMER SOC HEMATOLOGY. -
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785246. -
Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations
Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C. L., … Alizadeh, A. A. (2016). Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. BLOOD. AMER SOC HEMATOLOGY. -
Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., … Alizadeh, A. A. (2016). Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Circulating tumor DNA (ctDNA) in B-cell lymphoma
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating tumor DNA (ctDNA) in B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. WILEY. -
Reply to J. Wang et al.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2019). Reply to J. Wang et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801907. -
Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.
Albakr, A., Alhothali, W., Samghabadi, P., Maeda, L., Nagpal, S., & Ajlan, A. (2018). Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review. Cureus, 10(11), e3660. -
Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma
Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., … Alizadeh, A. A. (2018). Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. BLOOD, 132. -
Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2019). Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply. JOURNAL OF CLINICAL ONCOLOGY, 37(9), 755-+. -
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(28), 2845-+. -
Noninvasive molecular subtyping and risk stratification of DLBCL.
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Noninvasive molecular subtyping and risk stratification of DLBCL. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review
Albakr, A., Alhothali, W., Samghabadi, P., Maeda, L., Nagpal, S., & Ajlan, A. (2018). Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review. CUREUS, 10(11). -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Stereotactic Radiotherapy for Recurrent Post- Transplant Primary Central Nervous System Lymphoma
Benitez, C. M., Rahimy, E., Panjwani, N., Maeda, L. S., & Soltys, S. G. (2021). Stereotactic Radiotherapy for Recurrent Post- Transplant Primary Central Nervous System Lymphoma. CUREUS, 13(7). -
Stereotactic Radiotherapy for Recurrent Post-Transplant Primary Central Nervous System Lymphoma.
Benitez, C. M., Rahimy, E., Panjwani, N., Maeda, L. S., & Soltys, S. G. (2021). Stereotactic Radiotherapy for Recurrent Post-Transplant Primary Central Nervous System Lymphoma. Cureus, 13(7), e16537. -
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
Bennani, N. N., Tun, A. M., Carson, K. R., Geiger, J. L., Maeda, L. S., Savage, K. J., … Advani, R. H. (2021). Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma & Leukemia. -
Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
Bennani, N. N., Tun, A. M., Carson, K. R., Geiger, J. L., Maeda, L. S., Savage, K. J., … Advani, R. H. (2021). Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma & Leukemia. -
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., … Levy, R. (2022). CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. Blood Cancer Discovery. -
Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., … Levy, R. (2021). Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., … Levy, R. (2022). Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies »
- Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia »
- An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma »
- A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma »
- A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma »
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas »
- Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma »
- Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma »
Practice Locations
Lymphoma Program Palo Alto, CA
Palo Alto, CALymphoma Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Lymphoma Program in Palo Alto Palo Alto, CA
Palo Alto, CALymphoma Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(143 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

- Send referrals online
- View referral status
- Access medical records